Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BFRGNASDAQ:EQNASDAQ:GHSINASDAQ:LSTA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBFRGBullfrog AI$1.65-4.6%$1.75$1.23▼$4.84$15.54M0.62396,034 shs283,152 shsEQEquillium$0.33+1.4%$0.40$0.31▼$1.50$11.68M1.94435,898 shs109,108 shsGHSIGuardion Health Sciences$3.22-2.1%$3.24$3.04▼$18.00$4.35M0.73105,261 shs4,700 shsLSTALisata Therapeutics$2.48+2.1%$2.45$1.87▼$4.20$21.38M120,388 shs4,296 shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBFRGBullfrog AI0.00%-2.37%-10.81%-12.70%-9.09%EQEquillium0.00%-5.79%-19.48%-60.13%-50.77%GHSIGuardion Health Sciences0.00%0.00%0.00%0.00%-67.38%LSTALisata Therapeutics0.00%-0.84%-6.06%+6.44%-29.75%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBFRGBullfrog AI0.7075 of 5 stars0.05.00.00.00.02.50.0EQEquillium2.5845 of 5 stars3.25.00.00.01.11.70.6GHSIGuardion Health SciencesN/AN/AN/AN/AN/AN/AN/AN/ALSTALisata Therapeutics2.3384 of 5 stars3.53.00.00.01.70.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBFRGBullfrog AI 0.00N/AN/AN/AEQEquillium 2.33Hold$3.00817.71% UpsideGHSIGuardion Health Sciences 0.00N/AN/AN/ALSTALisata Therapeutics 3.00Buy$15.00504.84% UpsideCurrent Analyst Ratings BreakdownLatest GHSI, EQ, LSTA, and BFRG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2025EQEquilliumLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold3/28/2025EQEquilliumLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$3.00 ➝ $1.00(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBFRGBullfrog AI$60K259.05N/AN/A$0.57 per share2.89EQEquillium$41.10M0.28N/AN/A$0.54 per share0.61GHSIGuardion Health Sciences$12.25M0.35$0.14 per share23.15$6.39 per share0.50LSTALisata Therapeutics$1M21.38N/AN/A$3.49 per share0.71Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBFRGBullfrog AI-$6.99M-$0.81N/A∞N/AN/A-163.23%-139.94%N/AEQEquillium-$8.07M-$0.39N/AN/AN/A-19.62%-74.34%-46.75%8/6/2025 (Estimated)GHSIGuardion Health Sciences$160K$4.870.66∞N/A22.79%-73.69%-48.17%N/ALSTALisata Therapeutics-$19.99M-$2.30N/AN/AN/AN/A-61.37%-53.35%8/11/2025 (Estimated)Latest GHSI, EQ, LSTA, and BFRG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025BFRGBullfrog AIN/A-$0.21N/A-$0.21N/AN/A5/8/2025Q1 2025LSTALisata Therapeutics-$0.53-$0.55-$0.02-$0.55N/AN/A3/27/2025Q4 2024EQEquillium-$0.22-$0.16+$0.06-$0.16N/A$4.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBFRGBullfrog AIN/AN/AN/AN/AN/AEQEquilliumN/AN/AN/AN/AN/AGHSIGuardion Health Sciences$5.00155.28%N/A102.67%N/ALSTALisata TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBFRGBullfrog AIN/A4.874.87EQEquilliumN/A2.702.70GHSIGuardion Health SciencesN/A16.6816.59LSTALisata TherapeuticsN/A7.527.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBFRGBullfrog AI0.96%EQEquillium27.05%GHSIGuardion Health Sciences20.21%LSTALisata Therapeutics8.94%Insider OwnershipCompanyInsider OwnershipBFRGBullfrog AI33.90%EQEquillium30.30%GHSIGuardion Health Sciences1.32%LSTALisata Therapeutics9.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBFRGBullfrog AI49.42 million6.22 millionNot OptionableEQEquillium4035.72 million24.90 millionNot OptionableGHSIGuardion Health Sciences101.35 million1.33 millionNot OptionableLSTALisata Therapeutics308.62 million7.83 millionNot OptionableGHSI, EQ, LSTA, and BFRG HeadlinesRecent News About These CompaniesLisata and GATC to use AI for new opioid use disorder drugJune 18, 2025 | thepharmaletter.comLisata Therapeutics to lead development of opioid use disorder drug under expanded allianceJune 17, 2025 | proactiveinvestors.comLisata Therapeutics, Inc.: Lisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentJune 17, 2025 | finanznachrichten.deLisata Therapeutics to lead development of OUD therapy under expanded alliance with GATC HealthJune 17, 2025 | proactiveinvestors.comLisata Therapeutics and GATC Health Expand Relationship to Advance AI-Driven Drug Discovery and DevelopmentJune 17, 2025 | globenewswire.comLisata Therapeutics to Present at the 2025 BIO International ConventionJune 11, 2025 | globenewswire.comLisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comLisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ...May 10, 2025 | finance.yahoo.comLisata Therapeutics’ Earnings Call Highlights ProgressMay 9, 2025 | tipranks.comLisata Therapeutics Reports Q1 2025 Financial ResultsMay 9, 2025 | tipranks.comLisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call TranscriptMay 8, 2025 | seekingalpha.comLisata eyes key trial milestones in 2025 as certepetide development gains momentumMay 8, 2025 | proactiveinvestors.comLisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 8, 2025 | globenewswire.comLisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025May 1, 2025 | globenewswire.comLisata Therapeutics talks ADC breakthrough with Catalent – ICYMIApril 19, 2025 | proactiveinvestors.comLisata, Catalent partner for cancer drug researchApril 17, 2025 | uk.investing.comLisata Therapeutics signs research license with CatalentApril 15, 2025 | proactiveinvestors.comLisata Therapeutics Announces Research License with CatalentApril 15, 2025 | globenewswire.comLisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMIMarch 8, 2025 | proactiveinvestors.comLisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI TechnologyMarch 7, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyBy Jeffrey Neal Johnson | June 10, 2025View ASML’s AI Edge: How Its EUV Tech Is Creating a New MonopolyThis Banking Giant Just Got a $90 Price Target UpgradeBy Gabriel Osorio-Mazilli | June 6, 2025View This Banking Giant Just Got a $90 Price Target Upgrade3 Dividend Stocks Just Hiked Payouts 10%+ and Beat the MarketBy Leo Miller | May 27, 2025View 3 Dividend Stocks Just Hiked Payouts 10%+ and Beat the MarketWhy Schwab US Dividend Equity ETF Could Lead the Rotation By Gabriel Osorio-Mazilli | June 2, 2025View Why Schwab US Dividend Equity ETF Could Lead the Rotation GHSI, EQ, LSTA, and BFRG Company DescriptionsBullfrog AI NASDAQ:BFRG$1.65 -0.08 (-4.62%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.67 +0.02 (+1.21%) As of 06/20/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.Equillium NASDAQ:EQ$0.33 +0.00 (+1.36%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.32 -0.01 (-2.11%) As of 06/20/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.Guardion Health Sciences NASDAQ:GHSIGuardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.Lisata Therapeutics NASDAQ:LSTA$2.48 +0.05 (+2.06%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$2.44 -0.04 (-1.41%) As of 06/20/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
